Literature DB >> 11148480

The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata.

C Cotellessa1, K Peris, E Caracciolo, C Mordenti, S Chimenti.   

Abstract

BACKGROUND: Highly variable results of topical diphenylcyclopropenone (DPCP) in the treatment of alopecia areata have been reported so far.
OBJECTIVE: The purposes of our study were to evaluate the efficacy and tolerability of DPCP in the treatment of chronic, extensive alopecia areata and to assess the long-term overall benefit of treatment.
METHODS: Fifty-six patients with chronic, extensive alopecia areata were enrolled in an open-label clinical trial. After sensitization with 2% DPCP, progressively higher concentrations beginning at 0.001% were applied weekly for 6 to 12 months to one side of the scalp.
RESULTS: Fifty-two of 56 patients completed therapy. Total regrowth of terminal hair was achieved in 25 of 52 patients (48%) at 6 months. The most frequent side effect was an eczematous reaction at the site of application. Notably, persistent response was observed in 60% of these patients after 6 to 18 months of follow-up (mean, 12 months).
CONCLUSION: Topical DPCP treatment for alopecia areata is effective and well tolerated and provides prolonged therapeutic benefits.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11148480     DOI: 10.1067/mjd.2001.109309

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  13 in total

Review 1.  Lymphocytes, neuropeptides, and genes involved in alopecia areata.

Authors:  Amos Gilhar; Ralf Paus; Richard S Kalish
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 2.  Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.

Authors:  Ralph M Trüeb; Maria Fernanda Reis Gavazzoni Dias
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.

Authors:  A Sterkens; J Lambert; A Bervoets
Journal:  Clin Exp Med       Date:  2021-01-01       Impact factor: 3.984

4.  Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata.

Authors:  M Zöller; P Freyschmidt-Paul; M Vitacolonna; K J McElwee; S Hummel; R Hoffmann
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

5.  Extensive scalp angioedema following high-dose diphenylcyclopropenone for alopecia areata.

Authors:  Rachel Buchanan; Gloria Huynh; Jason Tanner
Journal:  Hosp Pharm       Date:  2014-01

6.  Topical immunotherapy in alopecia areata.

Authors:  Gurcharan Singh; Ms Lavanya
Journal:  Int J Trichology       Date:  2010-01

7.  Alopecia: evaluation and treatment.

Authors:  Katherine A Gordon; Antonella Tosti
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-07-19

8.  Diphencyprone induced vitiligo: a case report.

Authors:  Mohammad Ali Nilforoushzadeh; Gelavizh Keshtmand; Fariba Jaffary; Abbas Kheirkhah
Journal:  Case Rep Med       Date:  2012-07-01

9.  Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.

Authors:  Shahin Aghaei
Journal:  BMC Dermatol       Date:  2005-05-26

10.  A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata.

Authors:  Tueboon Sriphojanart; Saranya Khunkhet; Poonkiat Suchonwanit
Journal:  Dermatol Reports       Date:  2017-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.